logo-loader

Imugene receives $4.13 million R&D tax incentive boost for commercial and clinical milestones

Published: 19:32 11 Nov 2019 EST

Imugene Ltd (ASX:IMU) chief executive officer Leslie Chong and visiting US Professor Yuman Fong update Proactive on the progress of the company’s remarkable CF33 oncolytic virotherapy technology, which was acquired in July 2019.

Professor Fong is the inventor of the technology and spoke about the importance it will make to patients with a trial underway and making good progress.

The CEO also updates the market on a $4.13 Australian Government R&D tax incentive to help further develop commercial and clinical milestones.

Imugene doses first patient in PD1-Vaxx combination trial

Imugene Ltd (ASX:IMU, OTC:IUGNF) managing director and CEO Leslie Chong speaks with Proactive soon after announcing the first patient has been dosed in the combination cohort of the IMPRINTER study - a clinical trial to evaluate the safety and efficacy of Imugene’s PD1- Vaxx in combination with...

on 31/5/23